Leiphone interviews Leimang Bio on low-dose CAR-T at 1‰ of standard dose
AILeiphone AI Tech Review interviews Leimang Bio vice president Tong Duyue about its metabolism-enhanced CAR-T therapy, which uses 1‰ of the standard dose. The company reports 100% complete response in dozens of relapsed or refractory hematologic cancer and lupus patients, and says it has cut manufacturing cost to under 100,000 yuan, with a goal below 50,000 yuan.
AIWhy it matters.
The interview gives concrete dose, cost, and regulatory figures behind a counterintuitive CAR-T mechanism, useful for judging whether low-dose cell therapy can scale.
Source details
Leiphone · leiphone.comPublished · added here
Original title: 莱芒生物：用1‰剂量，重写CAR-T的成本和疗效公式